Physician profile
Michelle White
NPI 1326669532
$7,677.93
in general payments reported to CMS, 2019-2025
33 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,666 · 2022: $2,014 · 2023: $770 · 2024: $1,680 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,998.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,015.79 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $857.23 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $730.00 | 2021-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $645.27 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Alkermes, INC. | $551.72 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Tris Pharma INC | $546.53 | 2021-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Supernus Pharmaceuticals, INC. | $467.41 | 2021-2025 | Qelbree |
| Lundbeck LLC | $311.45 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $305.97 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.15 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $243.86 | 2021-2022 | |
| Indivior INC. | $191.75 | 2021-2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $187.97 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $156.47 | 2023-2025 | Ingrezza |
| Uswm, LLC | $154.65 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $148.16 | 2022-2024 | |
| Vanda Pharmaceuticals INC. | $136.55 | 2022-2025 | Fanapt, Hetlioz |
| Avanir Pharmaceuticals, INC. | $123.78 | 2021-2022 | |
| Corium, LLC | $116.46 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $94.68 | 2023-2024 | Auvelity |
| Eisai INC. | $66.77 | 2021-2022 | |
| Noven Therapeutics, LLC | $65.32 | 2023-2025 | Xelstrym, Secuado |
| Bausch Health US, LLC | $59.18 | 2022 | |
| Neos Therapeutics, LP | $55.67 | 2021-2022 | |
| Adlon Therapeutics L.P. | $46.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.10 | 2024 | Cobenfy |
| Owp Pharmaceuticals, INC. | $28.85 | 2021 | |
| Merck Sharp & Dohme LLC | $19.89 | 2022 | |
| Tempus Ai, INC | $17.79 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.31 | 2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $13.70 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.36 | 2024 | Relexxii |
| Bioxcel Therapeutics, INC. | $13.26 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.